Pain Management Laura Bergs FNP. Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant.

Slides:



Advertisements
Similar presentations
Prescription Drug Overdose National Perspective
Advertisements

Client satisfaction and perceptions of treatments in the North American Opiate Medication Initiative Kirsten Marchand, MSc Candidate at UBC SPPH Canadian.
Outpatient Treatment Ellen A. Ovson, M.D. Medical Director
Opioid Update F ederation of S tate M edical B oards Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain July 2013 F ederation.
Clinical Case Studies Developed by Dr. David Hunt.
The purpose is not to imply everyone on controlled substances will become addicted!!! Everyone on controlled substances is, however, at increased risk.
Neonatal Abstinence Syndrome. Risks for developing NAS Opioids – Opiate derivatives, interact with mu-opioid receptor Abstinence syndrome (withdrawal)
Controlling Off-Label Narcotics Usage - Impact of New Arizona Legislation ARS §
Update on the 2015 Agency Medical Directors’ Group’s (AMDG’s) Interagency Guideline on Prescribing Opioids for Pain.
Swinomish Wellness Program
Sublingual Buprenorphine and Pain
Withdrawal From Treatment. 3 Situations 1. Voluntary – patient and doctor agree it is time to taper and try to stop treatment 2. Voluntary – patient insists.
4th Annual Thoughtful Pain Management
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Pain Management at Stony Brook Medicine
The Pains of Chronic Opioid Usage
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Treatment for Adolescents With Depression Study (TADS)
Opioid Use in Work-related Injuries Pacific Northwest Chapter - Association of Occupational Health Professionals (AOHP) January 4, 2011 Jaymie Mai, PharmD.
For Pain or Not for Pain: Methadone Madness
Current Trends In Identifying And Treating Newborns With Withdrawal Syndromes 6/24/2010.
Medications for Pain: What You Need to Know for Treatment in Workers’ Compensation Suzanne Novak, MD, PhD 5/17/07.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Module IV: Identification of Patients for Buprenorphine Treatment BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals.
DRUGS OF ABUSE Reynaldo J. Lesaca, M.D. Reynaldo J. Lesaca, M.D.
Opioid Use in Workers’ Compensation Suzanne Novak, MD, PhD November 2008.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Use of Opioids fro Chronic Pain in Primary Care Norman Wetterau MD
Problem Behaviors Norman Wetterau. Less serious Ran of out pills three days early After one year lost pills Had a headache and a friend gave her a vicodin.
Katy Trinkley, PharmDAngie Thompson, PharmD.  Opioid risks and risk prevention strategies  Medication treatment by pain type  Fundamental principles.
+/- Opioid Management Kristen Zeller, M.D. Interventional Pain Management Specialist.
Opiate Management Douglas Keehn DO Adjunct Assistant Clinical Professor University Wisconsin Board Certified Anesthesia & Pain Management.
Don Teater MD Medical Advisor National Safety Council Itasca, IL Medical Provider Behavioral Health Group Asheville, NC Medical Provider Meridian Behavioral.
Addiction and dependence Disclaimer: This presentation contains information on the general principles of pain management. This presentation cannot account.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
HEIT TEMPLATE.PPT 1 The Ten Steps of Universal Precautions in Pain Medicine 1. 1.Diagnosis with appropriate differential 2. 2.Psychological assessment.
Pain Management: Narcotics, Implantable Therapies Maher Fattouh MD Adjunct Assistant Clinical Professor University Wisconsin Medical Director, Advanced.
Chronic Pain Management Harald Lausen, DO, MA FCM Clerkship SIU School of Medicine.
Prescribing Opioids in 2016: Still a Pain Jeff Varnell, M.D Cheyenne Mountain Resort April 15, 2016.
Safe Prescribing of Opioids for the Management of Chronic Nonterminal Pain La Tanya Austin, PGY3.
Opioids Tapering Melissa B. Weimer, DO, MCR. Disclosures Dr. Weimer is a consultant for INFORMed, IMPACT education, and the American Association of Addiction.
A System to Manage Long Term Opioid Prescribing in the Primary Care Setting Joy Nassar, MD University Medicine Foundation November 16, 2015.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
Terms Related to Substance Abuse
What Our Patients Look Like
Medications for Spine Pain
Current Concepts in Pain Management
Opioids for the management chronic non-cancer pain in Primary Care:
Larry Halverson, MD Gabrielle Curtis, MD Cox FMR Springfield MO
Avoid compassion traps
Tapering Opioids (1) C.L.I.P.S.
Medication-Assisted Therapy at Coleman Profession Services
MWCC.MS.GOV  Services  Medical Fee Schedule
Alcohol, Other Drugs, and Health: Current Evidence
Opioids Aware A resource for patients and HCPs to support prescribing of opioid medicines for pain Sue Mulvenna CDAO NHSE S SW March 2016.
STOP! Safe Treatment of Pain
Opioids – A Pharmaceutical Perspective on Prescription Drugs
What is Dementia? A term that describes a wide range of symptoms associated with a decline in memory or other thinking skills. Dementia may be severe.
Opioid Prescribing & Monitoring
Prescribing Opioids in Vermont
Controlled substance compliance
Prescription Drug Monitoring Program
Prescription Drug Monitoring Program
Essentials of Good Pain Care: A Team-Based Approach
Opioid prescribing workflow in the electronic medical record.
Guideline for the Treatment of Alcohol Use Disorder in the Outpatient Setting with Intramuscular Naltrexone Assess Candidacy for IM Naltrexone Meets DMS-V.
Medication Assisted Treatment of Opioid Use Disorder
Tapering and Discontinuing Chronic Opioid Therapy
Pain Management JEFFREY TAN HO, D.O.
Presentation transcript:

Pain Management Laura Bergs FNP

Definition of Chronic Pain Anyone with pain greater than 3 months Anyone with pain greater than 3 months Pain An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage Pain An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage Allodynia* Pain due to a stimulus that does not normally provoke pain. Allodynia* Pain due to a stimulus that does not normally provoke pain.

Regulations for monitoring Will do urine drug screen Will do urine drug screen Will not give narcotics unless off all illegal drugs Will not give narcotics unless off all illegal drugs Must follow pain management patient agreements and be consistent Must follow pain management patient agreements and be consistent

Urine Drug Screen

Metabolic Pathways 6- MAM HeroinMorphine

Metabolic Pathways Morphine Hydromorphone

Metabolic Pathway Codeine HydrocodoneHydromorphone

Urine drug testing Perform at initial visit, then random Perform at initial visit, then random Drug screen results are black and white Drug screen results are black and white False positives can occur in some instances False positives can occur in some instances Talk with toxicology if not sure of results Talk with toxicology if not sure of results All patients usually deny illegal drug use All patients usually deny illegal drug use Don’t have to treat patient, you did not decide to do the illegal drug, they did Don’t have to treat patient, you did not decide to do the illegal drug, they did

Tools assist to determine if narcotics needed COAT (chronic opioid analgesic therapy) COAT (chronic opioid analgesic therapy) pathway is a tool to be used by every pathway is a tool to be used by every provider prior to long term opioid therapy provider prior to long term opioid therapy Dire Score is used to determine if they are a candidate for opioid therapy Dire Score is used to determine if they are a candidate for opioid therapy Risk stratification-medium is the default risk Risk stratification-medium is the default risk

Inclusion Criteria COAT Inclusion Criteria COAT Group A not currently on opioid and considering opioid trial Group B on opioid < 3 months, considering continuing opioid Group C patient already on COAT

1st step in pathway DIRE Score Scoring based on Scoring based on DIRRRRE (Diagnosis, intractability, Risk, (psychological, chemical health, reliability, Social Support) Efficacy Score) DIRRRRE (Diagnosis, intractability, Risk, (psychological, chemical health, reliability, Social Support) Efficacy Score) Add D+I+4R+E=range Add D+I+4R+E=range Score 7-13 not suitable for COAT Score may be suitable The Journal of Pain, Vol 7, No 9 September, 2006 PP

Step 2: Risk Stratification Medium default risk Medium default risk Move to low risk if Move to low risk if Age > 65 years Age > 65 years Morphine equivalents <=10mg/d Morphine equivalents <=10mg/d Move to high risk if Move to high risk if Age<=35 Age<=35 Morphine equivalents >80mg/day Morphine equivalents >80mg/day Past substance use disorder Past substance use disorder Aberrant drug related behavior Aberrant drug related behavior Mental Illness Mental Illness Provider judgment Provider judgment

3 rd step monitoring Office visits based on risk, must see every three months Office visits based on risk, must see every three months Must have opioid agreement and informed consent Must have opioid agreement and informed consent Check state monitoring program before initiating COAT Check state monitoring program before initiating COAT Lab 7767 urine drug screen initial then randomized Lab 7767 urine drug screen initial then randomized Pill counts, I do with every visit, you may use your discretion Pill counts, I do with every visit, you may use your discretion

Risk stratification May keep in medium rather than move based on provider judgment Must document rational if meets high risk yet keep on med

Tapering of Opioid Decrease percent each week Decrease percent each week Round off the dose to the next available formulation Round off the dose to the next available formulation Symptoms can be managed with clonidine Symptoms can be managed with clonidine Consider adjuncts Consider adjuncts

Opioid agreement Random drug screens Random drug screens If found to have illegal's, If found to have illegal's, Can treat with adjuncts instead of narcotics Can treat with adjuncts instead of narcotics Chronic use of narcotic medication discouraged Chronic use of narcotic medication discouraged Wean off narcotics if not dependent/addicted Wean off narcotics if not dependent/addicted

Drugs of Abuse reference Guide Amphetamine speedDexedrineBenzadrine

Drugs of Abuse Reference Guide MDMA Ecstasy, XTC, ADAMLover’s speedmethylenedioxymethamphetamine

Drugs of Abuse Reference Guide Methamphetamine Speed, ice, crystal, crank DesoxymMethadrine

Deciding to take off Opioid At discretion of provider At discretion of provider If failed drug screen or documented drug diversion If failed drug screen or documented drug diversion DIRE score <14 DIRE score <14 may continue with no opioids may continue with no opioids

Weaning schedule 10 percent per week unless weaning off Methadone 10 percent per week unless weaning off Methadone Manage withdrawal symptoms Manage withdrawal symptoms May need to be inpatient May need to be inpatient Most can come off without any difficulty Most can come off without any difficulty If you discharge related to breach of contract do have legal obligation to follow for 30 days (this does not mean you have to prescribe narcotic) If you discharge related to breach of contract do have legal obligation to follow for 30 days (this does not mean you have to prescribe narcotic)

Section Y DIRE Score <14 If harm greater than benefit educate and taper If harm greater than benefit educate and taper Provider judgment that COAT benefits greater than harm-review at each visit Provider judgment that COAT benefits greater than harm-review at each visit Review with each visit: 4A’s: analgesia activity activity adverse effects adverse effects aberrant behavior aberrant behavior

Provider benefit greater than harm Documentation for effectiveness Documentation for effectiveness 4As plus 2As 4As plus 2As Analgesia Analgesia Activity Activity Adverse effects Adverse effects Aberrant behavior Aberrant behavior Assessment Assessment Action Action.bpismartform brief pain questionnaire

Illegal drug use Talk face to face with patient Talk face to face with patient Determine if they have an addiction Determine if they have an addiction You treat without narcotics You treat without narcotics Usually these patients self discharge Usually these patients self discharge High risk if you continue with narcotic and there is documentation of patient continuing with illegal drug use High risk if you continue with narcotic and there is documentation of patient continuing with illegal drug use

Taper off opioid Decrease percent per week Decrease percent per week Symptoms of abstinence syndrome, clonidine 0.1 mg every six hours or clonidine transdermal patch Symptoms of abstinence syndrome, clonidine 0.1 mg every six hours or clonidine transdermal patch May safely wean Methadone requires slower wean schedule 3% TAPER May safely wean Methadone requires slower wean schedule 3% TAPER Weekly visit with weaning Weekly visit with weaning

Weaning protocols Those that do not follow the rules Can use clonidine for withdrawal Refer to inpatient if able to find bed if on Methadone All other narcotics follow DIRE weaning protocol Those with no drug in urine are not taking the drug and do not need to be weaned

Weaning schedule If patient agrees to wean off If patient agrees to wean off Advantage-can try different drug once off all narcotics for two weeks Advantage-can try different drug once off all narcotics for two weeks Can tell if narcotic really did help with the pain, after several months of narcotic use they are not beneficial Can tell if narcotic really did help with the pain, after several months of narcotic use they are not beneficial Continue to monitor urine drug screens even after weaned off Continue to monitor urine drug screens even after weaned off

Patient and provider goals Need to set realistic goals with the patient Need to set realistic goals with the patient Most want all of their pain gone completely this is unrealistic if they have had pain for several years, some have just been discharged from another pain clinic Most want all of their pain gone completely this is unrealistic if they have had pain for several years, some have just been discharged from another pain clinic Review agreements with the patient often to prevent misunderstanding Review agreements with the patient often to prevent misunderstanding

Functional assessment Do not always go by pain level as stated Do not always go by pain level as stated Look at how dressed Look at how dressed How they are able to perform daily functions How they are able to perform daily functions Are they sedated Are they sedated Are they able to answer direct questions Are they able to answer direct questions When in doubt refer to me When in doubt refer to me

Adjunctive treatment Expect them to participate in therapy Expect them to participate in therapy Expect them to participate in daily exercise Expect them to participate in daily exercise Expect them to participate in psychotherapy Expect them to participate in psychotherapy Hope to start program for cognitive behavioral therapy for chronic pain Hope to start program for cognitive behavioral therapy for chronic pain State surveillance program for medications check this State surveillance program for medications check this

Stable chronic opioid patient No aberrant episodes and warrants continued therapy No aberrant episodes and warrants continued therapy Once stable prefer that PCP take over prescribing Once stable prefer that PCP take over prescribing Monitor monthly of every three months Monitor monthly of every three months Happy to see them back if they become unstable or wish to discontinue opioid therapy Happy to see them back if they become unstable or wish to discontinue opioid therapy

Any Questions

References pain.org/Content/NavigationMenu/GeneralRes ourceLinks/PainDefinitions/default.htm pain.org/Content/NavigationMenu/GeneralRes ourceLinks/PainDefinitions/default.htm